A Monte Carlo study of cellular S-factors for 1 keV to 1 MeV electrons
暂无分享,去创建一个
P. Hadjidoukas | H Nikjoo | C Bousis | D Emfietzoglou | P Hadjidoukas | H. Nikjoo | C. Bousis | D. Emfietzoglou | Hooshang Nikjoo
[1] D. Le Guludec,et al. Comparison of cellular and conventional dosimetry in assessing self-dose and cross-dose delivered to the cell nucleus by electron emissions of 99mTC, 123I, 111In, 67Ga and 201Tl , 1998, European Journal of Nuclear Medicine.
[2] Anirban Pathak,et al. A Monte Carlo study of energy deposition at the sub-cellular level for application to targeted radionuclide therapy with low-energy electron emitters , 2007 .
[3] J. Sempau,et al. PENELOPE-2006: A Code System for Monte Carlo Simulation of Electron and Photon Transport , 2009 .
[4] Geoff Delaney,et al. The role of radiotherapy in cancer treatment , 2005, Cancer.
[5] M. Bardiès,et al. A simplified approach to alpha dosimetry for small spheres labelled on the surface. , 1990, Physics in medicine and biology.
[6] G. Ferro-Flores,et al. Monte Carlo microdosimetry of 188Re- and 131I-labelled anti-CD20 , 2006, Physics in medicine and biology.
[7] Thomas F. Budinger,et al. MIRD primer for absorbed dose calculations , 1988 .
[8] Christophe Champion,et al. CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution—S Values for 131I in Spheres of Various Sizes , 2007, Journal of Nuclear Medicine.
[9] T. Wheldon,et al. The radiobiology of targeted radiotherapy. , 1990, International journal of radiation biology.
[10] R. K. Bull,et al. Stopping powers for electrons and positrons: ICRU Report 37; 271 pp.; 24 figures; U.S. $24.00. , 1986 .
[11] D. Oscier,et al. Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms. , 2003, Blood.
[12] A. Nahum. Microdosimetry and radiocurability: modelling targeted therapy with -emitters , 1996 .
[13] Wei Bo Li,et al. Track Structures and Dose Distributions from Decays of 131I and 125I in and around Water Spheres Simulating Micrometastases of Differentiated Thyroid Cancer , 2001, Radiation research.
[14] N Lanconelli,et al. Differences among Monte Carlo codes in the calculations of voxel S values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations. , 2009, Medical physics.
[15] A. Pathak,et al. Subcellular S-factors for low-energy electrons: A comparison of Monte Carlo simulations and continuous-slowing-down calculations , 2008, International journal of radiation biology.
[16] P. Hadjidoukas,et al. The effects of energy-loss straggling and elastic scattering models on Monte Carlo calculations of dose distribution functions for 10 keV to 1 MeV incident electrons in water , 2009 .
[17] B. Fallone,et al. Monte Carlo investigation of single cell beta dosimetry for intraperitoneal radionuclide therapy. , 2004, Physics in medicine and biology.
[18] J. Baró,et al. PENELOPE: An algorithm for Monte Carlo simulation of the penetration and energy loss of electrons and positrons in matter , 1995 .
[19] G. Barendsen,et al. Absorbed dose distribution of the auger emitters 67GA and 125I and the beta-emitters 67CU, 90Y, 131I, and 186RE as a function of tumor size, uptake, and intracellular distribution. , 1996, International journal of radiation oncology, biology, physics.
[20] Kostas Kostarelos,et al. A Monte Carlo track structure code for electrons (~10 eV-10 keV) and protons (~0.3-10 MeV) in water: partitioning of energy and collision events , 2000 .
[21] Franz Buchegger,et al. Auger radiation targeted into DNA: a therapy perspective , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[22] I. Gardin,et al. Modelling of the relationship between cell dimensions and mean electron dose delivered to the cell nucleus: application to five radionuclides used in nuclear medicine. , 1995, Physics in medicine and biology.
[23] I. Kawrakow. Accurate condensed history Monte Carlo simulation of electron transport. I. EGSnrc, the new EGS4 version. , 2000, Medical physics.
[24] H. Paretzke,et al. Comparison of Energy Deposition in Small Cylindrical Volumes by Electrons Generated by Monte Carlo Track Structure Codes for Gaseous and Liquid Water , 1994 .
[25] J. Fernández-Varea,et al. Comparison of Monte Carlo calculated electron slowing-down spectra generated by 60Co gamma-rays, electrons, protons and light ions. , 2002, Physics in medicine and biology.
[26] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. J. Strom,et al. Microdosimetric properties of ionizing electrons in water: a test of the PENELOPE code system. , 2002, Physics in medicine and biology.
[28] J. Fernández-Varea,et al. A relativistic optical-data model for inelastic scattering of electrons and positrons in condensed matter , 2005 .
[29] Calculations of Electron Single Event Distributions for Use in Internal Beta Microdosimetry , 1994 .
[30] M G Stabin,et al. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] J L Humm,et al. Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] G. Sgouros. Alpha-particles for targeted therapy. , 2008, Advanced drug delivery reviews.
[33] L. Gordon,et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. , 2004, Blood.
[34] A. Kassis. The MIRD approach: remembering the limitations. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] S. Adelstein,et al. Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] C. Tung,et al. Low-energy electron interactions with liquid water and energy depositions in nanometric volumes , 2007 .
[37] R. Böhm,et al. Monte Carlo Calculations of Energy Deposition in DNA for Auger Emitters , 2000 .
[38] David W. O. Rogers,et al. A Comparison of EGS and ETRAN , 1988 .
[39] H. Lundqvist,et al. Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies. , 2000, International journal of radiation oncology, biology, physics.
[40] M A Bernal,et al. An investigation on the capabilities of the PENELOPE MC code in nanodosimetry. , 2009, Medical physics.
[41] M. Stabin,et al. Nuclear medicine dosimetry , 2006, Physics in medicine and biology.
[42] Richard L Wahl,et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.
[43] I. Bernstein,et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.
[44] R. Howell,et al. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. , 1989, Medical physics.
[45] Comparison of Microdosimetric Simulations Using PENELOPE and PITS for a 25 keV Electron Microbeam in Water , 2002, Radiation research.
[46] T. Wheldon,et al. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[47] P. Hadjidoukas,et al. A Monte Carlo study of absorbed dose distributions in both the vapor and liquid phases of water by intermediate energy electrons based on different condensed-history transport schemes , 2008, Physics in medicine and biology.
[48] S. Goddu,et al. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] B Aubert,et al. Validation of the EGS usercode DOSE3D for internal beta dose calculation at the cellular and tissue levels. , 2003, Physics in medicine and biology.
[50] M. J. Berger. ESTAR, PSTAR, and ASTAR: Computer programs for calculating stopping-power and range tables for electrons, protons, and helium ions , 1992 .
[51] M Bardiès,et al. Dosimetry and microdosimetry of targeted radiotherapy. , 2000, Current pharmaceutical design.
[52] D. Georg,et al. Targeted radionuclide therapy: theoretical study of the relationship between tumour control probability and tumour radius for a 32P/33P radionuclide cocktail , 2008, Physics in medicine and biology.
[53] S. Goddu,et al. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] Kostas Kostarelos,et al. Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread. , 2007, Cancer biotherapy & radiopharmaceuticals.
[55] G. Sgouros. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] R. Stewart,et al. Monte Carlo simulation of DNA damage induction by x-rays and selected radioisotopes , 2008, Physics in medicine and biology.
[57] C. Punt,et al. Clinical applications of newer radionuclide therapies. , 2006, European journal of cancer.
[58] C. Divgi,et al. Current status of therapy of solid tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] A. Barrett,et al. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[60] A. Cole. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. , 1969, Radiation research.
[61] G T Chen,et al. Microdosimetric concepts in radioimmunotherapy. , 1993, Medical physics.
[62] Yong-ki Kim,et al. Extension of the binary-encounter-dipole model to relativistic incident electrons , 2000 .
[63] S. Chauvie,et al. Geant4 Physics Processes for Microdosimetry Simulation: Design Foundation and Implementation of the First Set of Models , 2007, IEEE Transactions on Nuclear Science.
[64] O. Press,et al. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience , 2000, Annals of Hematology.
[65] Herman Feshbach,et al. The Coulomb Scattering of Relativistic Electrons by Nuclei , 1948 .
[66] D. Rao,et al. Electron Dosimetry for Radioimmunotherapy: Optimal Electron Energy , 1985 .
[67] S. Strand,et al. Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma. , 2005, Cancer biotherapy & radiopharmaceuticals.
[68] C. Tung,et al. Calculations of cellular microdosimetry parameters for alpha particles and electrons. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[69] C. Zanelli,et al. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. , 1984, The International journal of applied radiation and isotopes.
[70] J A Parker,et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.
[71] P. Hadjidoukas,et al. Electron ionization cross-section calculations for liquid water at high impact energies , 2008 .
[72] R. Howell. The MIRD Schema: from organ to cellular dimensions. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[73] M. Brechbiel,et al. Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.